CV Sciences, Inc. (San Diego, CA), in collaboration with researchers from the University of California, San Diego, published a preclinical study demonstrating the effectiveness of chronic cannabidiol (CBD) treatment in reducing nicotine addiction through withdrawal symptoms.
“We are very pleased with the results of the research conducted in partnership with UC San Diego, which further validates our years of investment and hard work,” said Joseph Dowling, CEO of CV Sciences, in a press release. “This study marks an important milestone in CV Sciences’ research and development efforts in the treatment of smokeless tobacco addiction and expands our potential product development opportunities to commercialize the world’s first and only FDA-approved smokeless tobacco addiction treatment to meet a tremendous unmet medical need global health cover issue. “
In the animal study, nicotine-dependent rats with withdrawal symptoms were treated with CBD. The treatment prevented the animals from exhibiting withdrawal symptoms, including increased sensitivity to pain and weight gain, during short and long-term nicotine restriction.
This study follows the company’s formal notice of grant from the US Patent and Trademark Office (USPTO) in May 2020 for its patent application for a proprietary CBD and nicotine formulation that treats smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine. CV Sciences has also filed related patent applications that enable the company to seek similar patent protection in other key markets around the world.
- Smith LC et al. “Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats.” Psychopharmacology, Vol. 238 (2021): 2201-2211